{"data":{"id":1801,"lang":"en","title":"Kidney Drug Finerenone Found to Protect Heart and Kidneys in Millions More Patients, Including Non-Diabetics","summary":"New trials show Bayer's finerenone cuts kidney failure and heart risk by over 20%, extending benefits to millions of non-diabetic CKD patients.","category":"science","category_label":"Science","published_at":"2026-06-09T14:01:25Z","updated_at":"2026-06-09T14:01:25Z","url":"https://techtools.cz/tools/news/article/1801-kidney-drug-finerenone-found-to-protect-heart-and-kidneys-in-millions-more","api_url":"https://techtools.cz/news-api/v1/articles/1801?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/1801.md?lang=en","image_url":"https://scx1.b-cdn.net/csz/news/800a/2026/the-drug-finerenone-si.jpg","word_count":152,"reading_time_minutes":1,"sources":[{"url":"https://www.sciencedaily.com/releases/2026/06/260606075513.htm","domain":"sciencedaily.com"},{"url":"https://medicalxpress.com/news/2026-06-kidney-drug-finerenone-millions-patients.html","domain":"medicalxpress.com"},{"url":"https://www.bayer.com/en/us/news-stories/kerendia-for-non-diabetic-chronic-kidney-disease","domain":"bayer.com"}],"translation":{"lang":"cs","id":1874,"title":"Lék na ledviny finerenon chrání srdce i ledviny u milionů dalších pacientů, včetně nediabetiků","url":"https://techtools.cz/tools/news/clanek/1874-lek-na-ledviny-finerenon-chrani-srdce-i-ledviny-u-milionu-dalsich-pacientu","api_url":"https://techtools.cz/news-api/v1/articles/1874?lang=cs"},"content":"Bayer's finerenone (KERENDIA) sharply slows kidney disease and cuts cardiovascular risk in far more patients than current guidelines cover, according to results presented at the European Renal Association Congress in Glasgow and published simultaneously in The Lancet, The New England Journal of Medicine and JAMA.\n\nThe new FIND-CKD Phase 3 trial enrolled 1,584 people with non-diabetic chronic kidney disease across 24 countries and cut the combined risk of kidney failure, worsening CKD, heart failure, or cardiovascular death by 23%. A pooled analysis of 14,574 participants showed a 24% lower risk of kidney failure or disease progression and a 12% drop in death from any cause.\n\nThe findings matter because chronic kidney disease affects roughly 850 million people worldwide, about one in ten, and is projected to become the fifth leading cause of premature death by 2040. Crucially, the benefit now extends to non-diabetic patients, a group with few treatment options."}}